Partial
Mostly Aligned
Patient Risk:
Medium
Summary
Several claims align with the provided label excerpts (short-term adjunct, dosing concept, insomnia avoidance of late evening, specific adverse reactions, tolerance/abuse/dependence warning). However, multiple statements are either not specifically supported by the provided label text or overreach (e.g., “primarily used for short-term weight management” and “prescribed for individuals struggling with obesity” generally, “common side effects” phrasing, “more serious side effects” categories, “controlled in many countries,” and several market/patent/generic/other-drug claims are not addressed in the labeling excerpts).
Category Scores
Accurate Statements
Phentermine hydrochloride is a prescription medication primarily used for short-term weight management.
Label indicates short-term use: “short-term (a few weeks) adjunct” (Section 1) and “indicated only as short-term (a few weeks) monotherapy” (Section 5.1).
Phentermine hydrochloride is a stimulant that acts as an appetite suppressant.
Label describes pharmacologic activity similar to amphetamine and notes CNS stimulation and that appetite suppression is not definitively established as primary action: “It has not been established that the primary action… is… appetite suppression” (Section 12.1) and “Typical actions… include… central nervous system stimulation” (Section 12.2).
Common side effects of phentermine include insomnia.
Adverse reactions include “insomnia” (Section 6).
Common side effects of phentermine include constipation.
Adverse reactions include “constipation” (Section 6).
Common side effects of phentermine include nervousness.
Adverse reactions include “restlessness” (Section 6), which supports nervousness conceptually but is not verbatim.
More serious side effects of phentermine can involve increased heart rate.
Adverse reactions include “tachycardia” and “palpitation” (Section 6).
More serious side effects of phentermine can involve increased blood pressure.
Adverse reactions include “elevation of blood pressure” (Section 6) and warnings note “risk of increase in blood pressure” (Section 5.8).
More serious side effects of phentermine can include potential for dependence.
Warnings include “Risk of Abuse and Dependence” (Section 5.6).
Phentermine can cause psychiatric issues such as mood changes or hallucinations.
Adverse reactions include “euphoria, dysphoria” and “psychosis” (Section 6). (Hallucinations are not explicitly stated in the provided excerpts.)
Phentermine hydrochloride is generally recommended for short-term use due to the potential for tolerance and dependence.
Short-term/discontinuation with tolerance: “When tolerance… develops… rather, the drug should be discontinued.” (Section 5.4) and dependence/abuse risk: “Risk of Abuse and Dependence” (Section 5.6), plus short-term adjunct: Sections 1 and 5.1.
Unsupported Statements
Phentermine hydrochloride is typically prescribed in combination with diet and exercise for individuals struggling with obesity.
Label supports adjunct with exercise/behavior modification/caloric restriction (Section 1), but the claim says “typically prescribed in combination” (diet/exercise) without clear support for “typically prescribed” phrasing; also it does not explicitly state “struggling with obesity.”
Phentermine hydrochloride is prescribed for individuals with specific health risk factors such as high blood pressure, diabetes, or high cholesterol.
Label lists risk factors examples (controlled hypertension, diabetes, hyperlipidemia) in Section 1, but the claim uses broader phrasing (“specific health risk factors such as…”) that is not verbatim; partially supported rather than fully unsupported.
Common side effects of phentermine include dry mouth.
Label lists “Dryness of the mouth” (Section 6) but the claim uses “common side effects” categorization; the provided excerpts do not label these as “common.”
Phentermine hydrochloride prescription and dispensing are subject to strict regulations to ensure appropriate use and minimize risks.
No such regulatory/dispensing regulation statements appear in the provided label excerpts.
Regulatory bodies like the U.S. Food and Drug Administration (FDA) oversee phentermine approval and post-market surveillance.
No such statement appears in the provided label excerpts.
The primary patent protection for phentermine hydrochloride has long since expired.
Not addressed in the provided label excerpts.
Expiration of phentermine's primary patent protection has allowed for the introduction of generic versions of phentermine hydrochloride.
Not addressed in the provided label excerpts.
Generic versions of phentermine hydrochloride increase accessibility and competition in the market.
Not addressed in the provided label excerpts.
Beyond phentermine, other medications available for weight management include orlistat.
Not addressed in the provided label excerpts.
Beyond phentermine, other medications available for weight management include liraglutide.
Not addressed in the provided label excerpts.
Beyond phentermine, other medications available for weight management include semaglutide.
Not addressed in the provided label excerpts.
Beyond phentermine, other medications available for weight management include naltrexone-bupropion.
Not addressed in the provided label excerpts.
Beyond phentermine, other medications available for weight management include phentermine-topiramate.
Not addressed in the provided label excerpts.
Phentermine-topiramate is described as a later-generation formulation with a distinct patent and approval status.
Not addressed in the provided label excerpts for phentermine hydrochloride.
Phentermine hydrochloride is a controlled substance in many countries, including the United States.
No controlled substance classification statement appears in the provided label excerpts.
Phentermine hydrochloride is controlled due to its stimulant properties and potential for abuse.
The label excerpt supports abuse/dependence risk (Section 5.6) but does not state controlled substance legal rationale or controlled classification.
Contradictions
Important Omissions
Label-specific indication criteria and BMI thresholds (BMI ≥30 kg/m^2 or ≥27 kg/m^2 with other risk factors) are not included in the AI claims.
Importance:
Moderate
Key contraindications (e.g., pregnancy, nursing, MAOI use within 14 days, history of cardiovascular disease, hyperthyroidism, glaucoma, agitated states, history of drug abuse) are not mentioned.
Importance:
High
Dosing instructions (timing relative to breakfast, usual adult dose, half-tablet/half-tablets dosing adjustments, individualized lowest effective dose) are largely omitted.
Importance:
Moderate
Late evening administration avoidance for insomnia is only partially addressed (AI says insomnia is a side effect but does not reflect label instruction to avoid late evening).
Importance:
Moderate
Drug interaction details (MAOI contraindication within 14 days; alcohol interaction; insulin/oral hypoglycemics considerations; adrenergic neuron blocking drugs interaction) are not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Some safety-relevant label elements (short-term use, tolerance/discontinuation, abuse/dependence risk, insomnia, constipation, insomnia/psychiatric reactions, tachycardia/elevated BP) are reflected. However, multiple omissions of material contraindications and interactions could lead to incomplete safety understanding if used clinically.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Non-label claims (controlled substance status, FDA oversight, patent/generic/market competition, and other weight-loss drugs) are not supported by the provided prescribing information excerpts; key label contraindications/interactions and BMI criteria are omitted.
Suggested Improvement
Restrict claims to FDA label content provided (Sections 1, 2, 5, 6, 7, 8). Include BMI thresholds and contraindications/interactions (e.g., MAOIs within 14 days; pregnancy/nursing; cardiovascular disease history), and avoid asserting controlled-substance/legal/market/patent details or other drugs unless supported by the label excerpts.